Kronik Yarada TIME Yaklaşımı
Özet
Kronik yaralar, akut hasara verilen normal iyileşme yanıtı silsilesindeki kusurlar nedeniyle kronik bir döngü oluşturan ve kapanmayan tekrarlayan travma hâlleridir. Bu yaraların yönetiminde 2003 yılında ortaya konan yara yatağı hazırlığı kavramının ardından, 2004 yılında sürecin sistematik yönetimi için TIME (Tissue/Doku, Infection-Inflammation/Enfeksiyon-İnflamasyon, Moisture/Nem, Epithelial Edge/Epitel Sınırı) konsepti tanımlanmıştır. Doku basamağı yarayı nekrotik yükten arındırmayı amaçlarken; enfeksiyon ve inflamasyon basamağı iyileşmeyi geciktiren bakteriyel yükün ve glikokaliks temelli biyofilmlerin topikal veya sistemik yöntemlerle kontrol altına alınmasını hedefler. Nem basamağı, yetersiz veya aşırı eksüda varlığının yarattığı dengesizlikleri önleyerek ideal nem ortamını ve otolitik debridmanı sağlar; son basamak olan epitel sınırı ise yara dudaklarının ilerlemesini ve epitelizasyonu değerlendirir. TIME yaklaşımı, kronik yaraların bütüncül değerlendirilmesini sağlayarak negatif basınçlı yara tedavisi, ultrason, hiperbarik oksijen ve büyüme faktörleri gibi ileri tedavi metotlarının başarısını ve verimliliğini artıran bilimsel bir algoritma sunar.
Chronic wounds are non-healing and recurrent processes resulting from defects in the normal healing response sequence given to acute injuries. Following the concept of wound bed preparation introduced in 2003, the TIME (Tissue, Infection-Inflammation, Moisture, Epithelial Edge) concept was defined in 2004 for the systematic management of this process. While the tissue step aims to clear the wound of necrotic burden, the infection and inflammation step targets controlling the bacterial load and glycocalyx-based biofilms that delay healing through topical or systemic methods. The moisture step provides an ideal moist environment and autolytic debridement by preventing imbalances caused by insufficient or excessive exudate, whereas the final step, epithelial edge, evaluates the advancement of wound margins and epithelialization. The TIME approach provides a scientific algorithm that ensures a holistic evaluation of chronic wounds, thereby increasing the success and efficiency of advanced treatment methodologies such as negative pressure wound therapy, ultrasound, hyperbaric oxygen, and growth factors.
Referanslar
Schultz GS, Sibbald RG, Falanga V, Ayello EA, Dowsett C, HardingK, Romanelli M, Stacey MC, Teot L, Vanscheidt W. Wound bed preparation: a systematic approach to wound management. Wound Repair Regen2003;11:S1–28.
Bucalo B, Eaglstein WH, Falanga V. Inhibition of cell proliferation by chronic wound fluid. WoundRepair Regen 1993;1:181—6.
Raffetto JD, Mendez MV, Marien BJ, Byers HR,Phillips TJ, Park HY, Menzoian JO. Changes incellular motility and cytoskeletal actin in fibroblasts from patients with chronic venous insufficiency and in neonatal fibroblasts in the presence of chronic wound fluid. J Vasc Surg2001;33:233—41.
Mendez MV, Raffetto JD, Phillips T, Menzoian JO,Park HY. The proliferative capacity of neonatal skin fibroblasts is reduced after exposure to venous ulcer wound fluid: a potential mechanism for senescence in venous ulcers. J Vasc Surg 1999;30:734—43.
Falanga V. Classifications for wound bed preparation and stimulation of chronic wounds. Wound Repair Regen 2000;8:347—52.
Schultz GS, Barillo DJ, Mozingo DW, Chin GA. Wound bed preparation and a brief history of TIME.Int Wound J2004;1:19–32.
Harries RL, Bosanquet DC, Harding KG. Wound bed preparation: TIME for an update.Int Wound J 2016; 13 (suppl. S3):8–14
Falanga V. Wound bed preparation and the role of enzymes: a case for multiple actions of therapeutic agents. Wounds 2002;14:47—57.
Fowler E, van Rijswijk L. Using wound debridement to help achieve the goals of care. OstomyWound Manage 1995;41:23S—35S.
Gethin G, Cowman S, Kolbach DN. Debridement for venous leg ulcers.Cochrane Database Syst Rev2015;9:CD008599.
Smith F, Dryburgh N, Donaldson J, Mitchell M. Debridement for surgical wounds.Cochrane Database Syst Rev2013;9:CD006214.
Rodeheaver GT. Wound cleansing, wound irrigation, wound disinfection. In: Krasner D, Kane D, editors.Chronic wound care: a clinical source book for healthcare professionals. Wayne, PA: Health Management Publications, Inc,, 1997:97–108.
Harding KG, Moore K, Phillips TJ. Wound chronicity and fibroblast senescence--implications for treatment.Int Wound J2005;2:364–8.
Lukashev ME, Werb Z. ECM signalling: orchestrating cell behaviour and misbehaviour.Trends Cell Biol1998;8:437–41.
Leaper DJ, Schultz G, Carville K, Fletcher J, Swanson T, Drake R. Extending the TIME concept: what have we learned in the past 10 years? Int Wound J 2014; 9 (Suppl. 2):1–19
Sibbald RG, Williamson D, Orsted HL, Campbell K,Keast D, Krasner D, Sibbald D. Preparing the wound bed — debridement, bacterial balance and moisture balance. Ostomy Wound Manage 2000;46:14—35.
Sibbald RG, Orsted H, Schultz GS, Coutts P, Keast D.Preparing the wound bed 2003: focus on infection and inflammation. Ost Wound Mgt 2003;49:24—51.
Hoiby N, Bjarnsholt T, Moser C, Bassi GL, Coenye T, Donelli G,Hall-Stoodley L, Hola V, Imbert C, Kirketerp-Moller K, LebeauxD, Oliver A, Ullmann AJ, Williams C. ESCMID guideline for the diagnosis and treatment of biofilm infections 2014.Clin MicrobiolInfect2015;21:S1–25.
Thomson CH. Biofilms: do they affect wound healing?Int Wound J2011;8:63–7.
Attinger C, Wolcott R. Clinically addressing biofilm in chronic wounds.Adv Wound Care2012;1:127–32.
Jones V, Harding K, Stechmille J, Schultz G. Acute and chronic wound healing. In: Baranoski S, Ayello EA, editors.Wound care essentials practice principles. Philadelphia, PA: Lippincott, Williamsand Wilkins, 2007:64–76.
Hinman CD, Maibach H. Effect of air exposure and occlusion on experimental human skin wounds.Nature 1963;200:377—8.
Winter GD. Formation of scab and the rate of epithelisation of superficial wounds in the skin of the young domestic pig. Nature 1962;193:293—4.
Barnett A, Berkowitz RL, Mills R, Vistnes LM. Comparison of synthetic adhesive moisture vapor permeable and fine mesh gauze dressings for split-thickness skin graft donor sites. Am J Surg1983;145:379—81.
Mandy SH. A new primary wound dressing made of polyethylene oxide gel. J Dermatol Surg Oncol1983;9:153—5.
Phillips TJ, al-Amoudi HO, Leverkus M, Park HY. Effect of chronic wound fluid on fibroblasts.J Wound Care1998;7:527–32.
Trengove NJ, Bielefeldt-Ohmann H, Stacey MC. Mitogenic activity and cytokine levels in non-healing and healing chronic leg ulcers.Wound Repair Regen2000;8:13–25.
Dowsett C. Exudate management: a patient-centred approach.JWoundCare2008;17:249–52.
Eisenhardt SU, Schmidt Y, Thiele JR, Iblher N,Penna V, Torio-Padron N, Stark GB, BannaschH. Negative pressure wound therapy reduces the ischaemia/reperfusion-associated inflammatory response in free muscle flaps. J Plast ReconstrAesthet Surg 2011;65:640–9.
Ennis WJ, Valdes W, Gainer M, Meneses P. Evaluation of clinical effectiveness of MISTultrasound therapy for the healing of chronic wounds. Adv Skin Wound Care 2006;19:437–46.
Chambers AC, Leaper DJ. Role of oxygen in wound healing: a review of evidence. J Wound Care2011;20:160–4.
Iorio ML, Shuck J, Attinger CE. Wound healing in the upper and lower extremities: a systematic review on the use of acellular dermal matrices.Plast Reconstr Surg2012;130:232S–41.
Reyzelman AM, Bazarov I. Human acellular dermal wound matrixfor treatment of DFU: literature review and analysis.J Wound Care2015;24:128–34.
Brigido SA. The use of an acellular dermal regenerative tissue matrix in the treatment of lower extremity wounds: a prospective 16-week pilot study. Int Wound J2006;3:181–7.
Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB(becaplermin) in patients with chronic neuropathic diabetic ulcers. Aphase III randomized placebo-controlled double-blind study. DiabetesCare 1998;21:822–7.
Smiell JM, Wieman TJ, Steed DL, Perry BH,Sampson AR, Schwab BH. Efficacy and safety of becaplermin(recombinant human platelet-derived growth factor-BB) in patients with non-healing, lower extremity diabetic ulcers: a combined analysis of four randomized studies.Wound Repair Regen 1999;7:335—46.
Chin GA, Thigpin TG, Perrin KJ, Modawer LL,Schultz GS. Treatment of chronic ulcers in diabetic patients with a topical metalloproteinase inhibitor, doxycycline. Wounds 2003;15:315—23.
Bates-Jensen BM. Pressure ulcer assessment and documentation: the Pressure Sore Status Tool. In:Krasner D, Kane D, editors. Chronic wound care, 2nd edition. Wayne, PA: Health Management Publications, 1997:38.
